Denali Therapeutics Inc. — Director's Dealing 2023

Feb 15, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Denali Therapeutics Inc. (DNLI)
CIK: 0001714899
Period of Report: 2023-02-10

Reporting Person: Ho Carole (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-02-10	Common Stock	S	818	$29.80	Disposed	179365	Indirect
2023-02-13	Common Stock	S	2548	$30.10	Disposed	184285	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	25000	Indirect
Common Stock	119749	Direct

Footnotes

F1: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.

F2: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee.

F3: Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units.

F4: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $29.90 to $30.22 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F5: Reflects the issuance of shares to the Rohatgi-Ho Family 2009 Revocable Trust in connection with the vesting of 7,468 RSUs held by the Reporting Person.

F6: The shares are held of record by the Rohatgi-Ho Irrevocable GST Trust for the benefit of the Reporting Person's children.

F7: Includes 119,339 RSUs.